Claims
- 1. A composition comprising a blocking molecule that inhibits the biological activity of a CX3C motif of a respiratory syncytial virus G glycoprotein, wherein C is a cysteine residue and X is any amino acid residue other than cysteine.
- 2. The composition of claim 1, wherein the blocking molecule binds to the respiratory syncytial virus.
- 3. The composition of claim 1 wherein the CX3C motif is at amino acid positions 182-186 of a native respiratory syncytial virus G glycoprotein.
- 4. The composition of claim 1 wherein the blocking molecule is a drug, antibody, peptide, or polypeptide that binds to the CX3C motif of the RSV G glycoprotein.
- 5. The composition of claim 1 wherein the blocking molecule is a drug, antibody, peptide, or polypeptide that binds proximal to the CX3C motif and alters a secondary structure of the motif or sterically blocks respiratory syncytial virus G glycoprotein binding to a CX3C receptor or the biological activity associated with respiratory syncytial virus G glycoprotein binding to a CX3C receptor.
- 6. The composition of claim 1 wherein the blocking molecule is a drug, antibody, peptide, or polypeptide that binds to the CX3C receptor.
- 7. The composition of claim 1, wherein the blocking agent is a peptide having the sequence TCAAACKRIPNKK (SEQ ID NO: 5).
- 8. The composition of claim 1, wherein the blocking agent is a peptide having the sequence TCWAACKRIPNKK (SEQ ID NO: 6).
- 9. The composition of claim 1, wherein the blocking agent is a peptide having the sequence TCNAACKRIPNKK (SEQ ID NO: 7).
- 10. The composition of claim 1, wherein the blocking agent is a peptide having the sequence TCDAACKRIPNKK (SEQ ID NO: 8).
- 11. The composition of claim 1, wherein the blocking agent is a peptide having the sequence TCHAACKRIPNKK (SEQ ID NO: 9).
- 12. The composition of claim 1, wherein the blocking agent is a peptide having the sequence TCMAACKRIPNKK (SEQ ID NO: 10).
- 13. The composition of claim 1, wherein the blocking agent is a peptide having the sequence TCFAACKRIPNKK (SEQ ID NO: 11).
- 14. The composition of claim 1, wherein the blocking agent is a peptide having the sequence TCWAICKRIPNK (SEQ ID NO: 3).
- 15. The composition of claim 1, wherein the blocking agent is a peptide having the sequence NKKPGKKTTKP (SEQ ID NO: 4).
- 16. The composition of claim 1, wherein the blocking agent is an antibody that binds to the peptide having the sequence TCWAICKRIPNK (SEQ ID NO: 3).
- 17. The composition of claim 1, wherein the blocking agent is an antibody that binds to the peptide having the sequence NKKPGKKTTKP (SEQ ID NO: 4).
- 18. The composition of claim 1 wherein the biological activity is chemotaxis, cell migration or virus adherence to cells.
- 19. A respiratory syncytial virus comprising a CX3C motif of the respiratory syncytial G glycoprotein which is nonfunctional for attachment of the virus to a cell, wherein C is a cysteine residue and X is any amino acid residue other than cysteine.
- 20. The respiratory syncytial virus of claim 19 wherein the virus is a live virus.
- 21. The respiratory syncytial virus of claim 19 wherein the virus is a non-live virus.
- 22. A method of inducing an immune response in a subject, comprising administering an immunogenic amount of the composition of claim 1.
- 23. A method for identifying a substance useful for the treatment or prevention of respiratory syncytial virus disease comprising contacting the substance with a CX3C receptor, in the presence of respiratory syncytial virus G glycoprotein, and detecting inhibition of glycoprotein binding to the CX3C receptor, whereby detection of inhibition of respiratory syncytial virus G glycoprotein binding to the CX3C receptor identifies a substance useful for the treatment or prevetion of respiratory syncytial virus disease.
- 24. The method of claim 23, wherein the substance binds the CX3C motif of the respiratory syncytial virus G glycoprotein.
- 25. The method of claim 23, wherein the substance binds the CX3C receptor.
- 26. A method for identifying a substance for the treatment or prevention of respiratory synctial virus disease comprising contacting the substance with a CX3C receptor containing cell, in the presence of respiratory syncytial virus, and detecting inihibition of a biological activity associated with respriatory syncytial virus binding to the CX3C receptor, whereby detection of inhibition of a biological activity associated with respriatory syncytial virus binding to the CX3C receptor identifies a substance useful for the treatment or prevention of respiratory syncytial virus disease.
- 27. A method for treating respiratory syncytial virus infection in a subject infected with respiratory syncytial virus comprising administering to the subject an effective amount of the composition of claim 1 in a pharmaceutically acceptable carrier.
- 28. A method for treating respiratory syncytial virus infection in a subject infected with respiratory syncytial virus comprising administering to the subject an effective amount of the composition of claim 16 in a pharmaceutically acceptable carrier.
- 29. A method for treating respiratory syncytial virus infection in a subject infected with respiratory syncytial virus comprising administering to the subject an effective amount of the composition of claim 17 in a pharmaceutically acceptable carrier.
- 30. A method for preventing respiratory syncytial virus infection in a subject comprising administering to the subject an immunogenic amount of the virus of claim 19.
- 31. A method of inducing an immune response in a subject, comprising administering an immunogenic amount of the virus of claim 19.
- 32. A method of inducing an immune response in a subject, comprising administering an immunogenic amount of the composition of claim 1 in a pharmaceutically acceptable carrier.
- 33. A method of inducing an immune response in a subject, comprising administering an immunogenic amount of the composition of claim 16 in a pharmaceutically acceptable carrier.
- 34. A method of inducing an immune response in a subject, comprising administering an immunogenic amount of the composition of claim 17 in a pharmaceutically acceptable carrier.
Parent Case Info
[0001] This application is a continuation of and claims priority to international application PCT/US01/32459 filed on Oct. 18, 2001, which application is herein incorporated by reference in its entirety and which claims benefit of U.S. Provisional Application No. 60/241,521, filed on Oct. 18, 2000, and which application is herein incorporated by reference in its entirety.
Government Interests
[0002] This is invention was made at the Centers for Disease Control and Prevention. Therefore, the United States Government has certain rights in this invention.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60241521 |
Oct 2000 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
PCT/US01/32459 |
Oct 2001 |
US |
Child |
10420387 |
Apr 2003 |
US |